Perjeta (pertuzumab) / Roche - LARVOL DELTA

Her2climb-05: a randomized, double-blind, phase 3 study of tucatinib versus placebo in combination with trastuzumab and pertuzumab as maintenance therapy for her2+ metastatic breast cancer (SABCS 2025) - P3 | "In the HER2CLIMB-05 trial, the addition of tucatinib to TRAS + PERT as 1L maintenance therapy demonstrated a statistically significant and clinically meaningful improvement in PFS with a manageable safety profile in patients with HER2+ MBC."

Clinical • Combination therapy • Metastases • P3 data • Breast Cancer • HER2 Breast Cancer • HER2 Positive Breast Cancer • Hormone Receptor Breast Cancer • Hormone Receptor Positive Breast Cancer • HER-2

Trastuzumab Botidotin Versus Trastuzumab Emtansine in Human Epidermal Growth Factor Receptor 2-Positive Advanced Breast Cancer: A Phase III, Open-Label, Randomized Controlled Trial. (PubMed, J Clin Oncol) - P3 | "Among patients with HER2-positive advanced BC previously treated with trastuzumab and a taxane, trastuzumab botidotin resulted in significantly longer PFS than trastuzumab emtansine, with a distinct safety profile."

Journal • P3 data • Breast Cancer • Hematological Disorders • HER2 Breast Cancer • HER2 Positive Breast Cancer • Oncology • Solid Tumor • HER-2

A DESTINY-Breast09 (DB-)09 analysis of trastuzumab deruxtecan (T-DXd) + pertuzumab (P) vs taxane + trastuzumab + pertuzumab (THP) for patients (pts) with HER2+ advanced/metastatic breast cancer (a/mBC) and baseline (BL) brain metastases (BMs) (ESMO 2026) - No abstract available

Clinical • Late-breaking abstract • Metastases • Breast Cancer • HER2 Breast Cancer • HER2 Positive Breast Cancer • Oncology • Solid Tumor • HER-2

A case report on the management of sepsis complicated by eroded mixed hemorrhoids following breast cancer chemotherapy. (PubMed, Medicine (Baltimore)) - "This case demonstrates that in severely neutropenic and thrombocytopenic patients, a conservative, integrated approach combining systemic anti-infective therapy with advanced local wound care and traditional Chinese medicine can successfully manage life-threatening sepsis originating from eroded hemorrhoids. It underscores the critical importance of perianal hygiene, prompt management of chemotherapy-induced constipation and bone marrow suppression, and the potential of nonsurgical strategies in high-risk surgical candidates."

Journal • Breast Cancer • Chemotherapy-Induced Neutropenia • Constipation • Gastroenterology • Gastrointestinal Disorder • Hematological Disorders • HER2 Positive Breast Cancer • Infectious Disease • Neutropenia • Oncology • Septic Shock • Solid Tumor • Thrombocytopenia • HER-2

A Phase II study of pertuzumab+trastuzumab+capecitabine in Patients with taxans and trastuzumab refractory for advanced or recurrent breast cancer (clinicaltrials.gov) - P2 | N=30 | Enrolling by invitation | Sponsor: Saitama Breast Cancer Clinical Study Group | Unknown status ➔ Enrolling by invitation

Enrollment open • Breast Cancer • HER2 Breast Cancer • HER2 Positive Breast Cancer • Oncology • Solid Tumor • HER-2

Nodular Regenerative Hyperplasia Suggested by Noninvasive Findings during Adjuvant Trastuzumab Emtansine Therapy for Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer. (PubMed, Surg Case Rep) - "When new hepatic nodules develop during adjuvant T-DM1 therapy, T-DM1-associated NRH should be considered in the differential diagnosis. Although histological confirmation is required for a definitive diagnosis, noninvasive findings such as thrombocytopenia, splenomegaly, atypical EOB-MRI findings, and lesion stability may raise suspicion of NRH and help distinguish it from liver metastases."

Journal • Breast Cancer • Cardiovascular • Colon Cancer • Colorectal Cancer • Hematological Disorders • Hepatocellular Cancer • Hepatology • HER2 Breast Cancer • HER2 Positive Breast Cancer • Hormone Receptor Breast Cancer • Hormone Receptor Positive Breast Cancer • Hypertension • Liver Cancer • Oncology • Portal Hypertension • Solid Tumor • Thrombocytopenia • HER-2

Real-world treatment patterns and associated outcomes in patients with HER2-positive unresectable or metastatic breast cancer: the HER2 REAL Study. (PubMed, ESMO Open) - P | "This retrospective study shows heterogeneity in treatment patterns and survival outcomes in real-world patients with HER2-positive mBC, indicating the need for optimization of treatment in patients with HER2-positive mBC in real-world."

HEOR • Journal • Real-world evidence • Breast Cancer • HER2 Breast Cancer • HER2 Positive Breast Cancer • Oncology • Solid Tumor • HER-2

Pure Red Cell Aplasia Following Neoadjuvant Docetaxel/Carboplatin/Trastuzumab (TCbH) in a 45‑Year‑Old Woman With Breast Cancer Successfully Treated With Cyclosporine. (PubMed, Am J Case Rep) - "During the adjuvant trastuzumab/pertuzumab (HP) treatment, Hb remained ≥110 g/L. In this patient, cyclosporine was effective; after anemia correction, HP was tolerated. The observed gBRCA1 mutation is a hypothesis-generating finding requiring further validation."

Journal • Aplastic Anemia • Breast Cancer • Hematological Disorders • Hematological Malignancies • HER2 Breast Cancer • HER2 Positive Breast Cancer • Immunology • Infectious Disease • Oncology • Solid Tumor • Thymoma • Thymus Cancer • BRCA1 • HER-2

Socioeconomic and organizational impacts of subcutaneous fixed-dose combination (PH FDC SC) vs intravenous (P+H IV) pertuzumab and trastuzumab in HER2-positive breast cancer (BC): PHOCUS study in Korea (ESMO 2026) - No abstract available

Breast Cancer • HER2 Breast Cancer • HER2 Positive Breast Cancer • Oncology • Solid Tumor • HER-2

Transforming Access to Dual HER2 Blockade: Real-World Impact of Biosimilar Pertuzumab on Treatment Uptake and Financial Toxicity in India (ESMO 2026) - No abstract available

Clinical • Real-world • Real-world evidence • Oncology • HER-2

De-escalation of pertuzumab in node-negative HER2+ early breast cancer patients treated with neoadjuvant chemotherapy and trastuzumab (ESMO 2026) - No abstract available

Clinical • Breast Cancer • HER2 Breast Cancer • HER2 Positive Breast Cancer • Oncology • Solid Tumor • HER-2

Pharmacokinetics, safety, and immunogenicity of a biosimilar pertuzumab (BCD‑178) and reference pertuzumab in healthy subjects: results of a randomized, double-blind, comparative phase I clinical study (ESMO 2026) - No abstract available

Clinical • P1 data • PK/PD data • Oncology

Pertuzumab-based Regimens in HER2-positive Breast Cancer: a systematic review and meta-analysis of randomized controlled trials (ESMO 2026) - No abstract available

Retrospective data • Review • Breast Cancer • HER2 Breast Cancer • HER2 Positive Breast Cancer • Oncology • Solid Tumor • HER-2

Multicenter, phase II study of eribulin, carboplatin, trastuzumab and pertuzumab as neoadjuvant therapy in HER2-positive early or locally advanced breast cancer (ESMO 2026) - No abstract available

Clinical • Metastases • P2 data • Breast Cancer • HER2 Breast Cancer • HER2 Positive Breast Cancer • Oncology • Solid Tumor • HER-2

Real-world efficacy of first-line pertuzumab-based treatment for HER2-positive metastatic breast cancer in France: A French National Health Data System (SNDS) analysis (ESMO 2026) - No abstract available

Clinical • Metastases • Real-world • Real-world effectiveness • Real-world evidence • Breast Cancer • HER2 Breast Cancer • HER2 Positive Breast Cancer • Oncology • Solid Tumor • HER-2

Real-world implementation of pertuzumab from 2013 to 2023 for de Novo HER2-positive metastatic breast cancer: a population-based study of the Netherlands (ESMO 2026) - No abstract available

Clinical • Metastases • Real-world • Real-world evidence • Breast Cancer • HER2 Breast Cancer • HER2 Positive Breast Cancer • Oncology • Solid Tumor • HER-2

Real-World Comparative Study of Pertuzumab- vs Pyrotinib-Based First-Line Regimens in HER2-Positive Advanced Breast Cancer: A Xinjiang Multicenter Study (ESMO 2026) - No abstract available

Clinical • Metastases • Real-world • Real-world evidence • Breast Cancer • HER2 Breast Cancer • HER2 Positive Breast Cancer • Oncology • Solid Tumor • HER-2

Safety, social costs and quality of life (QOL) in HER2-positive (HER2+) breast cancer (BC) patients (pts) treated with Pertuzumab (P) and Trastuzumab (T) Fixed Dose combination (FDC): results from the prospective, observational, multicenter GIM30-RAPID study (ESMO 2026) - No abstract available

Clinical • HEOR • Observational data • Breast Cancer • HER2 Breast Cancer • HER2 Positive Breast Cancer • Oncology • Solid Tumor • HER-2

Updated results of SHR-A1811 plus pertuzumab in human epidermal growth factor receptor 2-positive (HER2+) unresectable/metastatic breast cancer: a phase 1b/2 study (ESMO 2026) - No abstract available

Metastases • P1/2 data • Breast Cancer • HER2 Breast Cancer • HER2 Positive Breast Cancer • Oncology • Solid Tumor • HER-2

IBI354 plus pertuzumab as first-line (1L) treatment for patients (pts) with HER2-positive, unresectable locally advanced or metastatic breast cancer (BC): Results from a phase 2 study (ESMO 2026) - No abstract available

Clinical • Metastases • P2 data • Breast Cancer • HER2 Breast Cancer • HER2 Positive Breast Cancer • Oncology • Solid Tumor • HER-2

Trastuzumab and pertuzumab in HER2 overexpressed/ERBB2 amplified, treatment refractory metastatic colorectal cancer: Merged data from patients treated in the DRUP, FINPROVE, IMPRESS-Norway and ProTarget trials. (ESMO 2026) - No abstract available

Clinical • Metastases • Colorectal Cancer • Oncology • Solid Tumor • HER-2

Radiation Therapy Followed by Intrathecal (IT) Trastuzumab/Pertuzumab in the Management of HER2+ Breast Leptomeningeal Metastasis: Results from a Phase II Multi-Institutional Study, (INSPIRE-LM) (ESMO 2026) - No abstract available

Clinical • P2 data • Breast Cancer • Oncology • Solid Tumor • HER-2

BRIDGET: A Phase II trial of tucatinib added to trastuzumab/pertuzumab or ado-trastuzumab emtansine after isolated intracranial progression in patients with advanced HER2-positive breast cancer (ESMO 2026) - No abstract available

Clinical • Metastases • P2 data • Breast Cancer • HER2 Breast Cancer • HER2 Positive Breast Cancer • Oncology • Solid Tumor • HER-2

Health-Related Quality of Life from HER2CLIMB-05: A Phase 3 Study of Tucatinib Versus Placebo in Combination with Trastuzumab and Pertuzumab as 1L Maintenance Therapy for HER2+ mBC (ESMO 2026) - No abstract available

Clinical • Combination therapy • HEOR • P3 data • HER2 Positive Breast Cancer • Oncology • HER-2

DESTINY-Breast11: MRI-assessed objective responses during neoadjuvant treatment (NAT) with trastuzumab deruxtecan (T-DXd) followed by paclitaxel + trastuzumab + pertuzumab (THP) vs dose-dense doxorubicin + cyclophosphamide followed by THP (ddAC-THP) in HER2+ early breast cancer (eBC) (ESMO 2026) - No abstract available

Clinical • Breast Cancer • HER2 Breast Cancer • HER2 Positive Breast Cancer • Oncology • Solid Tumor • HER-2